Roche

Roche scores—again—in hemophilia drug patent case against Takeda
Fierce Pharma
Thu, 09/21/23 - 11:47 am
Roche
Takeda
patents
legal
Genentech
Baxalta
hemophilia
Roche hits FDA delay with subcutaneous version of Tecentriq amid manufacturing process changes
Fierce Pharma
Thu, 09/7/23 - 10:53 pm
Roche
FDA
Tecentriq
Halozyme
Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win
BioSpace
Thu, 09/7/23 - 10:49 pm
Alnylam
Roche
PAH
zilebesiran
clinical trials
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Merck’s Keytruda to top drug sales in 2028, as Roche takes pharma crown
Medical Marketing and Media
Fri, 08/25/23 - 09:55 am
Merck
Keytruda
Roche
branding
Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors
BioSpace
Thu, 08/24/23 - 11:50 am
Roche
Genentech
divarasib
KRAS inhibitors
solid tumors
clinical trials
Roche, Horizon lead way for pharma reputation among rare disease patient groups
Medical Marketing and Media
Wed, 08/23/23 - 05:49 pm
Roche
Horizon Pharma
reputation
rare disease
Roche posts interim TIGIT overall survival data after 'inadvertent disclosure,' sending stocks up
Fierce Biotech
Wed, 08/23/23 - 10:10 am
Roche
Tigit
clinical trials
lung cancer
non-small cell lung cancer
tiragolumab
Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown
Fierce Pharma
Mon, 08/21/23 - 10:52 am
Merck
Roche
pharma sales
Keytruda
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Daiichi Sankyo will remain 'dominant' in ADC market for oncology treatments
Biopharma Reporter
Mon, 08/7/23 - 10:14 am
Daiichi Sankyo
antibody drug conjugate
oncology
Seagen
Roche
Filings signal: Despite Covid losses, pharma earnings are promising
Clinical Trials Arena
Wed, 08/2/23 - 11:32 am
Takeda
AstraZeneca
Roche
earnings
COVID-19
Phase III trial results bring subcutaneous Ocrevus closer to its potential approval
Clinical Trials Arena
Mon, 07/31/23 - 10:09 am
Roche
Ocrevus
clinical trials
MS
multiple sclerosis
Roche Drops Hemophilia A Candidate, Prepares for the Impacts of IRA
BioSpace
Thu, 07/27/23 - 11:36 am
Roche
RG6358
Spark Therapeutics
hemophilia A
earnings
Roche Decides Not to Exercise Solid Tumor Option with SQZ
BioSpace
Tue, 07/25/23 - 08:51 pm
Roche
solid tumors
SQZ Biotech
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
BioSpace
Mon, 07/24/23 - 11:29 am
Roche
Alnylam
RNAi
hypertension
zilebesiran
Roche’s Vabysmo reports positive outcomes in multiple eye diseases
Clinical Trials Arena
Thu, 07/20/23 - 10:04 am
Roche
Vabysmo
diabetic macular edema
wet age-related macular degeneration
Scratching the surface of the urticaria pipeline
EP Vantage
Thu, 07/20/23 - 10:00 am
chronic urticaria
Sanofi
Dupixent
Regeneron
Novartis
Roche
Xolair
Allakos
AstraZeneca
Celldex Therapeutics
Roche, mirroring Novartis, guilty of most serious marketing breach for Polivy website
Fierce Pharma
Mon, 07/17/23 - 08:44 am
Roche
PMCPA
pharma marketing
Polivy

Pages